HeartSciences is advancing the field of electrocardiography through the use of wavelet signal processing and artificial intelligence to develop next-generation ECG technology to provide valuable new insights and information that focus on the early detection of heart disease. HeartSciences seeks to bridge today’s “diagnostic gap” in cardiac care by providing front line, low-cost, effective solutions that assist in the early detection of heart disease in at-risk patients.
Formed in 2008, HeartSciences (formerly known as Heart Test Laboratories) is a privately held medical technology company located in the Dallas-Fort Worth metroplex, the largest economic area in the Southern United States. HeartSciences’ MyoVista wavECG Device benefits from more than ten years of research and development to enable the early detection of heart disease to fundamentally improve the ability of an ECG to detect structural and ischemic heart disease.
The MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device applies proprietary use of Continuous Wavelet Transform (CWT) signal processing and represents HeartSciences first product release from years of research and development.
The MyoVista Device is not FDA cleared and is not available in the United States.